

Marco Chiumente

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2846839/publications.pdf>

Version: 2024-02-01

42
papers

188
citations

1306789

7
h-index

1281420

11
g-index

45
all docs

45
docs citations

45
times ranked

195
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors. <i>Frontiers in Oncology</i> , 2019, 9, 453.	1.3	23
2	The Life Cycle of Health Technologies. Challenges and Ways Forward. <i>Frontiers in Pharmacology</i> , 2017, 8, 14.	1.6	22
3	A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival Curves. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 66-68.	0.3	15
4	Comorbidity, Polytherapy, and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs. <i>Journal of Pharmacy Practice</i> , 2018, 31, 58-65.	0.5	13
5	CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 292-299.	0.2	10
6	Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials. <i>Cureus</i> , 2021, 13, e19893.	0.2	8
7	The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors. <i>Cureus</i> , 2022, 14, e21065.	0.2	8
8	A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1261-1264.	0.6	8
9	Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. <i>Journal of Chemotherapy</i> , 2017, 29, 245-251.	0.7	6
10	Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 525-535.	0.7	6
11	Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 787-792.	0.5	6
12	Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median. <i>Acta Haematologica</i> , 2020, 143, 598-599.	0.7	6
13	Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 134-138.	0.5	5
14	CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 490-491.	0.2	5
15	The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 349-354.	1.0	5
16	Toward a common understanding of competencies for health technology assessment: enhancing educational and training programs around the globe. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e29.	0.2	5
17	Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method. <i>Cureus</i> , 2022, 14, e22645.	0.2	5
18	Burden of Stroke in Italy: An Economic Model Highlights Savings Arising from Reduced Disability following Thrombolysis. <i>International Journal of Stroke</i> , 2015, 10, 849-855.	2.9	4

#	ARTICLE	IF	CITATIONS
19	Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies. <i>Immunotherapy</i> , 2021, 13, 95-101.	1.0	4
20	Rituximab biosimilar evaluated by network meta-analysis. <i>Haematologica</i> , 2017, 102, e497-e498.	1.7	3
21	Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093064.	1.4	3
22	Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 271-273.	1.2	2
23	Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 29-34.	0.2	2
24	Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 160-162.	0.3	2
25	Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 9-10.	0.6	2
26	Promoting the use of Markovian simulation models to study outcomes of thrombectomy after acute ischemic stroke. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 777-779.	0.6	1
27	OP127 Analysis Of The Competencies To Be Acquired In Health Technology Assessment. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 59-59.	0.2	1
28	Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 222, 84-88.	0.5	1
29	SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces. <i>European Journal of Hospital Pharmacy</i> , 2021, , ejhpharm-2021-002692.	0.5	1
30	Experience in managing independent clinical research, the best training strategy for future clinical pharmacists: the QOSMOS project. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 364-364.	0.5	1
31	Hospital Pharmacy Response to Covid-19 Pandemic in Italy: What We Learned From the First Outbreak Wave. <i>Journal of Pharmacy Practice</i> , 2023, 36, 87-95.	0.5	1
32	Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2021, , .	0.3	1
33	Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 1881-1889.	0.5	1
34	First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. <i>Immunotherapy</i> , 2022, 14, 871-877.	1.0	1
35	Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression. <i>Journal of Chemotherapy</i> , 2020, 32, 268-271.	0.7	0
36	COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e7-e7.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke. <i>Journal of Stroke</i> , 2016, 18, 230-232.	1.4	0
38	Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumab. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 41-42.	0.3	0
39	Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available. <i>European Journal of Hospital Pharmacy</i> , 2020, , ejhpharm-2020-002609.	0.5	0
40	HTA Metro Map: a patient centred model for optimizing the decision making process. <i>GMS Health Innovation and Technologies</i> , 2019, 15, Doc02.	0.0	0
41	Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use. <i>European Journal of Hospital Pharmacy</i> , 2021, , ejhpharm-2021-003157.	0.5	0
42	The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis. <i>Neurology International</i> , 2021, 13, 682-694.	1.3	0